
Ixo et al. in €7.3m round for Antabio
A number of French investors including Ixo Private Equity and Galia Gestion have taken part in a €7.3m round for biotechnology company Antabio.
The series-A round included investments from Ixo, Irdi Soridec Gestion, Galia Gestion and the company's previous investors.
The fresh funding has been earmarked to advance Antabio's programmes into clinical studies, accelerating the development of the company's attempt to treat infections caused by pathogens.
Antabio was previously financed through a number of non-dilutive grants.
Company
Antabio is a French biopharmaceutical company developing antibacterial treatments, aiming to fill a gap in the treatment of drug-resistant infections.
Advisers
Equity – Chammas et Marcheteau, Antonin Cubertafond, Romain Penloup (legal).
Company – McDermott Will & Emery, Anthony Paronneau, Laetitia De Dinechin, Chloé Huertas (legal).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds